Application of spermidine in preventing and treating calcified aortic valve disease
By using spermidine as a drug component, the calcium ion concentration in calcified aortic valve disease is reduced and the inflammatory response is inhibited, solving the high-risk surgical problem in the treatment of calcified aortic valve disease in existing technologies and achieving the effectiveness and safety of drug therapy.
Patent Information
- Application Number
- CN202411269736.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-15
Smart Images

Figure BDA0005038348170000051 
Figure BDA0005038348170000061
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of prevention and treatment of calcified aortic valve, in particular to the use of spermidine in preventing and treating calcified aortic valve disease. Background Art
[0002] Calcific aortic valve disease (CAVD) is a pathological process involving lipid deposition, chronic inflammatory regulation, and progressive calcification. The fibrous activation and osteoblast differentiation (calcification) of the valvular interstitial cells, the main cell component of the aortic valve, is considered to be the key link in CAVD. This calcification process can make the valve tissue rigid and inflexible, affecting the normal movement and function of the valve and having an adverse effect on the normal functioning of the heart.
[0003] Currently, the main treatment for valvular calcification is surgery, such as aortic valve replacement, aortic decalcification and percutaneous balloon valvuloplasty. However, surgery will inevitably bring higher risks to patients, such as high perioperative mortality and poor long-term effects. Therefore, it is urgent to develop drug treatment options that can effectively delay or prevent the progression of CAVD. Summary of the invention
[0004] The purpose of the present invention is to provide the use of spermidine in preventing and treating calcific aortic valve disease, so as to solve the problems raised in the above background technology.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] Use of spermidine in preventing and treating calcific aortic valve disease.
[0007] As a further solution of the present invention: the spermidine is a compound extracted from wheat germ; its compound registration number is 124-20-9, its chemical formula is C7H19N3, and its molecular weight is 145.2.
[0008] As a further embodiment of the present invention, the calcific aortic valve disease includes aortic valve stenosis, aortic aneurysm formation, heart failure, arrhythmia, cerebral infarction, aortic dissection and myocardial infarction.
[0009] As a further solution of the present invention: the effect of spermidine in preventing and treating calcific aortic valve disease is at least manifested in one of the following:
[0010] 1) Reduce the calcium ion concentration in the aortic valve interstitial cells;
[0011] 2) Remove free radicals in the body and reduce oxidative stress levels;
[0012] 3) Inhibit the expression of inflammatory factors;
[0013] 4) Inhibit apoptosis of aortic valve cells;
[0014] 5) Regulate the BMP signaling pathway in aortic valve cells.
[0015] As a further solution of the present invention: the spermidine is used to prepare a drug for preventing and treating calcific aortic valve disease, and the active ingredient concentration of spermidine in the prepared drug is 80-120 μmol / L.
[0016] As a further solution of the present invention: the concentration of the active ingredient of spermidine in the prepared medicine is 80 μmol / L.
[0017] As a further solution of the present invention: the concentration of the active ingredient of spermidine in the prepared medicine is 90 μmol / L.
[0018] As a further solution of the present invention: the concentration of the active ingredient of spermidine in the prepared medicine is 100 μmol / L.
[0019] As a further solution of the present invention: the concentration of the active ingredient of spermidine in the prepared medicine is 110 μmol / L.
[0020] As a further solution of the present invention: the concentration of the active ingredient of spermidine in the prepared medicine is 120 μmol / L.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention provides a use of spermidine in preventing and treating calcific aortic valve disease, which can significantly reduce the calcification process of vascular smooth muscle cells; can inhibit the production of multiple pro-inflammatory cytokines, such as IL-6 and MCP-1, etc., and by reducing the inflammatory response, spermidine helps to reduce the pathological damage of CAVD and delay the progression of the disease; spermidine can promote cell autophagy, thereby helping to remove calcium salts and other harmful substances accumulated in the aortic valve and reduce the formation of calcified nodules; and spermidine has a strong antioxidant capacity, can remove free radicals in the body, reduce oxidative damage, and protect aortic valve cells from oxidative stress; in summary, spermidine can significantly delay the pathological process of CAVD and reduce the formation of calcified nodules and damage to the aortic valve through multiple pathways such as inhibiting calcification of vascular smooth muscle cells, anti-inflammation, promoting cell autophagy and anti-oxidation. DETAILED DESCRIPTION
[0023] Embodiment 1
[0024] In the embodiment of the present invention, spermidine is used for preventing and treating calcific aortic valve disease, and the active ingredient concentration of spermidine in the prepared medicine is 80 μmol / L.
[0025] Embodiment 2
[0026] In the embodiment of the present invention, spermidine is used for preventing and treating calcific aortic valve disease, and the concentration of the active ingredient of spermidine in the prepared medicine is 90 μmol / L.
[0027] Embodiment 3
[0028] In the embodiment of the present invention, spermidine is used for preventing and treating calcific aortic valve disease, and the concentration of the active ingredient of spermidine in the prepared medicine is 100 μmol / L.
[0029] Embodiment 4
[0030] In the embodiment of the present invention, spermidine is used for preventing and treating calcific aortic valve disease, and the concentration of the active ingredient of spermidine in the prepared medicine is 110 μmol / L.
[0031] Embodiment 5
[0032] In the embodiment of the present invention, spermidine is used for preventing and treating calcific aortic valve disease, and the concentration of the active ingredient of spermidine in the prepared medicine is 120 μmol / L.
[0033] Comparative Example 1
[0034] Atorvastatin was selected, and the concentration of the active ingredient in the prepared medicine was selected to be 100 μmol / L.
[0035] Comparative Example 2
[0036] Furosemide is selected, and the concentration of the active ingredient in the prepared medicine is selected to be 100 μmol / L.
[0037] Comparative Example 3
[0038] Aspirin is selected, and the concentration of the active ingredient in the prepared medicine is selected to be 100 μmol / L.
[0039] In order to further illustrate the technical effect of the present invention, the following experiments are performed to verify:
[0040] Obtain appropriate valvular interstitial cells and perform cell culture, culture 10 valvular interstitial cell culture media, and induce calcification in 9 of them. Specifically, use the same concentration of vitamin D3 (VD3) to induce calcification in the 9 culture media, and after the induction, take out 8 of them, use one experimental example or comparative ratio for inhibition treatment for each of them, and do not perform any inhibition treatment on the remaining one;
[0041] After 72 hours of culture, the calcified nodules of the valve interstitial cells stained with Alizarin red, the relative values of the expression of osteogenic proteins in the valve interstitial cells (the valve interstitial cells were stained with immunohistochemistry, and Runx2 and Osteoponin were selected as two indicators), and the relative values of the expression of inflammatory factors related to the valve interstitial cells (the expression of IL-8, IL-6, and MCP-1 in the valve interstitial cells was detected by PCR, i.e., the mRNA expression) were detected and the following three tables were prepared;
[0042] Note: All data were expressed as mean ± standard deviation (x ± s) using SPSS16.0 statistical software; t-test was used for pairwise comparison, and P < 0.05 was considered statistically significant.
[0043] Table 1 Calcification nodules of valvular interstitial cells stained with Alizarin red
[0044] Experimental items Calcified nodules / field of view No calcification induction 3.1±0.7 No inhibition after calcification induction 21.2±1.5 Embodiment 1 8.2±0.2 Embodiment 2 8.3±0.5 Embodiment 3 7.8±0.7 Embodiment 4 7.9±0.2 Embodiment 5 8.0±0.4 Comparative Example 1 11.4±0.7 Comparative Example 2 11.1±0.3 Comparative Example 3 10.5±0.4
[0045] It can be concluded from Table 1 that the calcified nodule areas of the embodiment and the comparative example are smaller than those of the non-inhibited example after calcification induction;
[0046] From this, we can analyze that spermidine can effectively reduce the calcium ion concentration in the aortic valve interstitial cells, thereby preventing and treating calcific aortic valve disease.
[0047] Table 2 Expression of osteogenic proteins in valvular interstitial cells (relative value)
[0048] Experimental items Runx2 Osteoponin No calcification induction 1 1 No inhibition after calcification induction 4.0±0.5 6.1±0.2 Embodiment 1 1.6±0.2 3.2±0.3 Embodiment 2 1.4±0.5 3.0±0.3 Embodiment 3 1.5±0.4 3.0±0.4 Embodiment 4 1.7±0.4 3.2±0.6 Embodiment 5 1.6±0.3 3.1±0.1 Comparative Example 1 2.1±0.5 3.8±0.6 Comparative Example 2 1.9±0.2 3.8±0.5 Comparative Example 3 2.0±0.4 3.7±0.5
[0049] It can be concluded from Table 2 that the expression levels of ossification proteins in the examples and comparative examples are lower than those in the no inhibition example after calcification induction;
[0050] From this, we can analyze and conclude that spermidine can inhibit the expression of solidified proteins, thereby reducing the calcium ion concentration in the aortic valve interstitial cells, and thus preventing and treating calcific aortic valve disease.
[0051] Table 3 Expression of inflammatory factors related to valve interstitial cells (relative value)
[0052]
[0053]
[0054] It can be concluded from Table 3 that the mRNA expression levels of the Examples and Comparative Examples were less than that of the No Inhibition Example after calcification induction;
[0055] From this, we can analyze that spermidine can effectively inhibit the expression of mRNA, thereby inhibiting the expression of inflammatory factors, and then preventing and treating calcific aortic valve disease.
[0056] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.
[0057] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. Use of spermidine in preventing and treating calcific aortic valve disease.
2. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The spermidine is a compound extracted from wheat germ; its compound registration number is 124-20-9, its chemical formula is C7H19N3, and its molecular weight is 145.
2.
3. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The calcific aortic valve diseases include aortic stenosis, aortic aneurysm formation, heart failure, arrhythmia, cerebral infarction, aortic dissection and myocardial infarction.
4. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The effect of spermidine in preventing and treating calcific aortic valve disease is at least manifested in one of the following: 1) Reduce the calcium ion concentration in the aortic valve interstitial cells; 2) Remove free radicals in the body and reduce oxidative stress levels; 3) Inhibit the expression of inflammatory factors; 4) Inhibit apoptosis of aortic valve cells; 5) Regulate the BMP signaling pathway in aortic valve cells.
5. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The spermidine is used for preparing medicine for preventing and treating calcific aortic valve disease, and the effective ingredient concentration of spermidine in the prepared medicine is 80-120 μmol / L.
6. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The effective ingredient concentration of spermidine in the prepared medicine is 80 μmol / L.
7. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The effective ingredient concentration of spermidine in the prepared medicine is 90 μmol / L.
8. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The effective ingredient concentration of spermidine in the prepared medicine is 100 μmol / L.
9. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The effective ingredient concentration of spermidine in the prepared medicine is 110 μmol / L.
10. Use of spermidine according to claim 1 in preventing and treating calcific aortic valve disease, It is characterized in that The effective ingredient concentration of spermidine in the prepared medicine is 120 μmol / L.
Citation Information
Cited By
Cell in-vitro calcification inducer, induction culture medium and application thereof, aortic valve calcification in-vitro induction model and modeling method of aortic valve calcification in-vitro induction model
CN121931035A
